anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BCL-2 family members are known to be implicated in survival in numerous biological settings. Here, we provide evidence that in injury and repair processes in lungs, BCL-2 mainly acts to attenuate endoplasmic reticulum (ER) stress and limit extracellular matrix accumulation. Days after an intratracheal bleomycin challenge, mice lose a fraction of their alveolar type II epithelium from terminal ER stress driven by activation of the critical ER sensor and stress effector IRE1α. This fraction is dramatically increased by BCL-2 inhibition, because IRE1α activation is dependent on its physical association with the BCL-2-proapoptotic family member BAX, and we found BCL-2 to disrupt this association in vitro. In vivo, navitoclax (a BCL-2/BCL-xL inhibitor) given 15-21 days after bleomycin challenge evoked strong activation of IRE-1α in mesenchymal cells and markers of ER stress, but not apoptosis. Remarkably, after BCL-2 inhibition, bleomycin-exposed mice demonstrated persistent collagen accumulation at Day 42, compared with resolution in controls. Enhanced fibrosis proved to be due to the RNAase activity of IRE1α downregulating MRC2 mRNA and protein, a mediator of collagen turnover. The critical role of MRC2 was confirmed in precision-cut lung slice cultures of Day-42 lungs from bleomycin-exposed wild-type and MRC2 null mice. Soluble and tissue collagen accumulated in precision-cut lung slice cultures from navitoclax-treated, bleomycin-challenged mice compared with controls, in a manner nearly identical to that of challenged but untreated MRC2 null mice. Thus, apart from mitochondrial-based antiapoptosis, BCL-2 functions to attenuate ER stress responses, fostering tissue homeostasis and injury repair.
Patients will receive Gabapentin pre-operatively on-call 120 minutes prior to surgery starting. Patients at the conclusion of surgery will have additional doses of Ofirmev (IV Tylenol) and Gabapentin via IV based on patients pre-operative weight. Post surgery the patient will be transitioned to oral pain medications (Tylenol and Gabapentin) with rescue medications available for breakthrough pain control.
A solution, in particular for hemodialysis or peritoneal dialysis that permits attaining a desired glucose concentration without affecting the concentrations of other components in the solution. The solution consists of at least three individual solutions that are combined and administered after heat sterilization. The first solution contains calcium ions, electrolyte salts and optionally glucose in a concentration of 0-1000 mM and is acidified to a pH of less than 4.0 with a physiologically tolerable acid. The second solution contains glucose in a concentration different from that of the first solution and the remaining components of the first solution in the same concentration. The third solution contains a buffer in the physiological range. Also provided is a method of preparing a solution according to the invention, where the desired mixing ratio of the separate solutions is automatically established by a dialysis machine or peritoneal dialysis cycler.
OBJECTIVE: Randomized controlled trials indicate regional anesthesia (RA) improves postoperative outcomes with reduced pain and opioid consumption. Therefore, we hypothesized children who received RA, regardless of technique, would have reduced pain/opioid use in routine practice.
METHODS: Using a retrospective cohort, we assessed the association of RA with perioperative outcomes in everyday practice at our academic pediatric hospital. Patients 18 years or below undergoing orthopedic, urologic, or general surgeries with and without RA from May 2014 to September 2021 were categorized as single shot, catheter based, or no block. Outcomes included intraoperative opioid exposure and dose, preincision anesthesia time, postanesthesia care unit (PACU) opioid exposure and dose, PACU antiemetic/antipruritic administration, PACU/inpatient pain scores, PACU/inpatient lengths of stay, and cumulative opioid exposure. Regression models estimated the adjusted association of RA with outcomes, controlling for multiple variables.
RESULTS: A total of 11,292 procedures with 3160 RAs were included. Compared with no-block group, single-shot and catheter-based blocks were associated with opioid-free intraoperative anesthesia and opioid-free PACU stays. Post-PACU (ie, while inpatient), single-shot blocks were not associated with improved pain scores or reduced opioid use. Catheter-based blocks were associated with reduced PACU and inpatient opioid use until 24 hours postop, no difference in opioid use from 24 to 36 hours, and a higher probability of use from 36 to 72 hours. RA was not associated with reduced cumulative opioid consumption.
DISCUSSION: Despite adjustment for confounders, the association of RA with pediatric pain/opioid use outcomes was mixed. Further investigation is necessary to maximize the benefits of RA.
Embodiments of a pharmaceutical formulation comprising an enteric material are disclosed. The embodiments release at least a portion of an active ingredient upon contacting gastric fluid. The remaining portion of the formulation releases active ingredient upon contacting intestinal fluid. Certain embodiments of the pharmaceutical composition comprise at least one active ingredient in a core and a leaky enteric coating, such as an enteric coating comprising a gastric fluid channeling agent. Other embodiments of the pharmaceutical composition comprise at least one active ingredient substantially homogeneously admixed with at least one enteric material, such as an enteric material comprising a gastric fluid channeling agent. Disclosed embodiments of the pharmaceutical composition may comprise a single active ingredient, or may comprise plural active ingredients. Generally, but not necessarily, the active ingredient has a window of absorption. The present disclosure also describes a method for treating a subject having a condition treatable by an active ingredient. The method comprises providing one or more embodiments of the pharmaceutical composition disclosed herein comprising an active ingredient suitable for treating the condition. The pharmaceutical composition is administered to the subject. A method for making embodiments of the disclosed composition also is described. The method comprises providing a core comprising an active ingredient. An enteric material is applied to at least a portion of the core, and generally on or about a substantial portion of the core, to form a coat. The composition is then made leaky.
Participants allocated to this group will receive 18 sessions of therapeutic exercise program based on the PNF concept (Bello et al. 2011).
In adult subjects with renal impairment, the apparent oral clearance of entecavir decreased as creatinine clearance decreased [see Clinical Pharmacology (12.3)]. Dosage adjustment is recommended for patients with creatinine clearance less than 50 mL/min, including patients on hemodialysis or continuous ambulatory peritoneal dialysis (CAPD), as shown in Table 2. The once-daily dosing regimens are preferred.

* If administered on a hemodialysis day, administer Entecavir tablets after the hemodialysis session.

Pediatric use information is approved for Bristol-Myers Squibb Company’s Baraclude (entecavir) tablets. However, due to Bristol-Myers Squibb Company’s marketing exclusivity rights, this drug product is not labeled with that information.
To assess the clinical efficacy of Double Filtration Plasmapheresis (DFAPP), a novel blood purification method, in treating hyperlipidemic moderate/severe pancreatitis (HL-M/SAP). A total of 68 HL-M/SAP patients were enrolled in this study. The observation group, comprising 34 patients, received DFAPP treatment, while the control group underwent CVVH + PA treatment. We compared the efficacy changes between the two groups post-treatment. Patients treated with DFAPP showed significant improvements in clinical outcomes. After 72 h of DFAPP treatment, HL-M/SAP patients exhibited notably lower multiple organ failure scores and a reduced mortality rate compared to those in the CVVH + PA group. Triglyceride levels in HL-M/SAP patients treated with DFAPP for 48 h averaged 3.75 ± 1.95, significantly lower than the 9.57 ± 3.84 levels in the CVVH + PA group (P < 0.05). Moreover, CRP levels decreased markedly, IL-17 levels diminished, IL-10 levels increased, and the decline in IL-35 levels was significantly less pronounced compared to the CVVH + PA group. The recurrence rate of pancreatitis was also significantly lower after 6 months. The early implementation of DFAPP in HL-M/SAP patients effectively reduces triglyceride levels, suppresses pro-inflammatory factors, enhances anti-inflammatory factors, and mitigates cytokine storm-induced sepsis damage. Consequently, this leads to a decrease in the incidence of multiple organ failure, improved patient survival rates, and a reduce the recurrence rate of lipogenic pancreatitis.Trial registration: Chinese Clinical Trial Registry, ChiCTR2300076066.
50 individuals with WS will take part in the study. All participants will be recruited from the Williams Syndrome Clinic at Edmond and Lili Safra Children's Hospital, Sheba Medical Center directed by Prof. Doron Gothelf, MD, that coordinates treatment and research of WS in Israel. 20 control age-matched subjects will be recruited as well. A Motor Questionnaire, designed especially for this study will be filled by parents. It includes questions about gross motor, fine motor, gait and coordination characteristics of the children (Bellugi, Bihrle et al. 1990, Wilson, Kaplan et al. 2000, Wilson, Crawford et al. 2009) (General references regarding motor abilities and health).

In addition, participants will undergo the following assessments at the neuromuscular clinic and at the movement laboratory, Sheba Medical Center in collaboration with Dr. Amir Dori, Dr. Uri Givon and Dr. Meir Plotnik: (1) nerve conduction study (2) nerve ultrasound (3) neurological assessments (4) GAITRite walkway for gait analysis (5) 3-D motion analysis.
The invention relates to a hybridoma cell strain secreting an anti-CpHV-1 monoclonal antibody and application thereof, belonging to the technical field of immunity. The invention screens out a hybridoma cell strain 4A4 from an established hybridoma cell bank secreting an anti-CpHV-1 monoclonal antibody. The mouse ascites monoclonal antibody prepared by the method has a neutralizing titer of 2 to CpHV-1 8 . The monoclonal antibody secreted by the hybridoma cell 4A4 strain can be used for clinical treatment of CpHV-1 diseased sheep, and has the advantages of obvious curative effect, safety and no adverse side effect. The monoclonal antibody therapeutic agent prepared from the hybridoma cell 4A4 strain has no reduction of neutralization potency after being stored for two years, and has good stability. In addition, the indirect Immunofluorescence (IFA) detection method established by using the monoclonal antibody secreted by the hybridoma cell 4A4 strain as a detection antibody has better sensitivity and specificity, and can be used for differential diagnosis of CpHV-1 infection.
<P>PROBLEM TO BE SOLVED: To provide a sustained-release preparation with enhanced entrapment of physiologically active polypeptides, suppressing initial leakage after administration and a constant long-term release of the physiologically active polypeptides and to provide a method for producing the preparation.  <P>SOLUTION: This invention provides a sustained-release preparation dispersing and forming the physiologically active polypeptides into an organic solvent liquid of a metal salt of a biodegradable polymer and provides the method for producing the preparation. It is preferable that fine particles of the sustained-release preparation has 0.1-300 μm in size and the preparation is an injection agent. An aliphatic polyester, particularly α-hydroxycarboxylic acid polymer is preferably used as the biodegradable polymer. Hormones (especially insulin or growth hormone) or cytokine (especially interferon) is preferably used as the physiologically active polypeptide.  <P>COPYRIGHT: (C)2009,JPO&INPIT
Dry eye is a chronic condition that is believed to afflict more than 3 million patients in the United States.1 Symptoms of dry eye are very bothersome and impact quality of life, reduce work capacity, and may result in poorer psychological health. Also, symptoms of dry eye are associated with a decreased ability to perform activities that require visual attention such as reading and driving a car.2 Patients with dry eye complain most frequently of a scratchy or sandy (foreign body) sensation. Other common symptoms are itching, excessive mucus secretion, inability to produce tears, a burning sensation, photosensitivity, redness, pain, and difficulty in moving the lids. In most patients, the most remarkable feature of the eye examination is the grossly normal appearance of the eye.3 Chronic dry eye disease is associated with an inflammatory mechanism mediated by activated T-cell lymphocytes3 which affects the ocular surface and lacrimal gland.4 The damage caused by dry eye disease may be irreversible, and despite the availability of various tear substitutes, many patients with dry eye syndrome experience corneal injuries with a subsequent reduction in vision.5 Cyclosporin A (Restasis®, Allergan, Irvine, CA) has been shown to significantly reduce the number of activated T-lymphocytes within the conjunctiva6, thereby minimizing the inflammation causing dry eye. Topical cyclosporin A 0.05% ophthalmic emulsion (Restasis®, Allergan, Irvine, CA) increases tear production and improves the quality of naturally produced tears and is the first approved therapeutic agent for the treatment of chronic dry eye and the only treatment modality that addresses the underlying pathology.

In addition to topical therapy with cyclosporine, some patients continue to use artificial tears for occasional relief of residual symptoms. The choice of concomitant tear is important but little research has been published differentiating between the efficacy of these solutions when used concomitantly with topical cyclosporine.
Patients will breathe on APAP for 6 weeks simulating normal therapy. Usage, leak, P95/P90 and AHI will be recorded and averaged over the duration.
Autoantibodies, Lupus-like syndrome, autoimmune hepatitis, as Adverse Reactions of Enbrel subcutaneously vs. Adverse Reactions of Enbrel subdermally at Week 36.
Aging is associated with declines in muscle mass, physical strength and physical function. Adequate quality protein intake in aging adults is critical to preventing functional decline. Peanuts provide a unique blend of amino acids that can provide several health benefits to aging adults. While supplementing with peanut protein (PP) powder as part of a resistance training program may increase myofibrillar protein synthesis (i.e., the gold standard molecular assessment in deciphering a muscle-building response), and improve skeletal muscle quality and body composition, no study to date has made this determination.

This is a two-phase study using both novel and conventional methods to assess how PP supplementation affects muscle tissue in older individuals who engage in resistance training. These two phases will be conducted as part of a 10-week randomized controlled trial in which men and women aged 50 years and older (n=60), will be stratified by gender and randomized to a resistance training intervention (whole body, two days per week) with PP powder (72g daily; n=15 males, n=15 females) provided during the intervention (immediate group, IG) or after the intervention (wait-list control, WLC, n=15 males, n=15 females). The aims of this study are to determine the acute (deuterium oxide tracer) and chronic (peripheral quantitative computed tomography) effects of PP during resistance training on skeletal muscle myofibrillar protein synthesis rates, changes in skeletal muscle size and quality, changes in whole and appendicular body composition (dual energy x-ray absorptiometry), changes in inflammatory markers and the fecal microbiome.
The invention discloses a pharmaceutical composition with the dysmenorrheal-resistant efficacy and a preparation method of the pharmaceutical composition. The pharmaceutical composition is composed of three active components including cyperotundone, alpha-cyperone and sugeonol. When dysmenorrheal-resistant biological effect experiment comparison is carried out on the pharmaceutical composition prepared by the three effective compounds mixed in different proportions, the result shows that when the mass ratio of the cyperotundone to the alpha-cyperone and to the sugeonol is 43:41:16, the dysmenorrheal-resistant efficacy is remarkably enhanced. The pharmaceutical composition has the beneficial effects that the pharmaceutical composition is the optimum composition of four-method prepared rhizoma cyperi dysmenorrheal-resistant efficacy active components; and in the aspect of the active components, matching research is performed among the active components, and the dysmenorrheal-resistant biological effect of the four-method prepared rhizoma cyperi is greatly improved. Traditional Chinese medicine active component compatibility eliminates interference of non-medicine-efficacy substances, and new discovery of traditional Chinese medicine component drugs is facilitated. Various effective preparations for clinical application can be conveniently developed, and new dosage form research is facilitated.
A computer-implemented method 100 for predicting a growth rate of an aortic aneurysm comprises analysing 110 one or more geometric measures of a volumetric model of at least a portion of an aorta having an aneurysm, and determining 120, from the analysis, a growth rate prediction for the aortic aneurysm. The prediction may be a categorical growth rate prediction or a continuous growth rate prediction. One geometric measure of the model may be the curvature of a path through the model and/or a branchpoint angle at a branchpoint of the model. The model may be obtained from a computed tomography (CT) image of the aorta of a patient and may be of an abdominal aortic aneurysm (AAA). One geometric measure may be shape-based such as the ellipticity of the aorta or the surface irregularity of the model. The model measurements may be compared to previously obtained reference measurements for reference aortas having aneurysms of known growth rate.
AFCAS study is an observational, multi-center, prospective registry including patients with atrial fibrillation undergoing PCI-S. Follow-up time is 12 months.

Primary end points are major hemorrhagic and thrombotic/thromboembolic complications including cardiac death and secondary endpoints are Major adverse cardiac events (i.e., need for urgent re-revascularization, myocardial infarction, death), stent thrombosis and major/non major hemorrhagic complications. Clinical follow-up will be completed for all patients via telephone, or clinic visits scheduled at 1, 3, 6, and 12 months after PCI-S. The 1 and 6 months visits are optional. The patients will be asked about their clinical outcomes, hospitalizations and medications. Any additional information needed, such as specific mortality, will be obtained by contacting one of the patient's physicians or other health care professional or from death certificates. CRFs will be completed and faxed without delays after discharge, and after each follow up visit. Recruitment will take approximately 12 months. Follow-up will be 12 months for each patient.
The invention relates to a 2-phenylnaphthalene derivative and a preparation method and application thereof. The 2-phenylnaphthalene derivatives are FL-2 and FL-3. The invention also provides a preparation method of the 2-phenylnaphthalene derivatives FL-2 and FL-3, and application of the 2-phenylnaphthalene derivatives in preparation of topoisomerase II catalytic inhibitor and antitumor drugs. The invention reports the application of the 2-phenylnaphthalene derivative in the preparation of a TopoII alpha catalytic inhibitor for the first time. The 2-phenylnaphthalene derivatives FL-2 and FL-3 provided by the invention have strong topoisomerase II inhibiting activity and show certain topoisomerase II alpha subtype selectivity. On a cellular level, the expression of topoisomerase II is inhibited, so that the tumor cell proliferation can be obviously inhibited, and the topoisomerase II catalytic inhibitor can be used in the development of antitumor drugs.
The updated ESAIC guideline on postoperative delirium (POD) comprises a total of 13 recommendations, including five with the recommendation grade "strong": 1.) The assessment of preoperative POD risk factors, 2.) the optimisation of the preoperative condition, 3.) the discussion of prevention strategies, 4) the implementation of a non-pharmacological multicomponent intervention in patients at risk of POD and 5.) the risk-benefit assessment of the prophylactic administration of dexmedetomidine. The latter applies in particular due to the partly contradictory data situation and different areas of application (cardiac surgery versus non-cardiac surgery patients). Index-based EEG monitoring of the depth of anaesthesia is also recommended, whereby other parameters such as burst suppression and density spectral array should also be included. If non-pharmacological measures fail, POD should be treated with haloperidol. In contrast, the use of benzodiazepines is not recommended.
The investigators will prospectively examine whether an aerobic training intervention will alter markers of immune cell aging (i.e. increase telomerase activity in peripheral blood mononuclear cells, telomere length in peripheral blood mononuclear cells and leukocytes, mitochondrial function, epigenetic profiles, and mRNA expression), improve exercise capacity and blood pressure, and decrease psychological distress over 24 weeks in 32 caregivers compared to 32 age-matched wait list control caregivers. Our sample will be comprised of caregivers who provide unpaid care for a family member diagnosed with Alzheimer's disease or other dementia. Participants in the study will be highly stressed and inactive male and female caregivers of family members with Alzheimer's disease or other dementia. All eligible participants will complete one week of ecological momentary assessments (EMA) to examine whether (1) previously unfit, high-stressed caregivers benefit psychologically from becoming active, (2) this benefit is derived through changes in how caregivers react to and recover from stressful events, and (3) whether these salubrious psychological effects mediate changes in biological outcomes (e.g., cellular aging). Next, participants will participate in a one-week run-in period of stretching 30 minutes on 4 separate days prior to randomization to guarantee that the investigators are randomizing well-informed participants that are willing and able to complete the expected exercise. Next, participants are randomized into the aerobic exercise or wait list control arm. In the 24th week of the study, participants complete a second week of the EMAs sub-study, and return after week 24 for a final blood draw.

Research study assessments consist of self-report questionnaires, body composition, physical performance and fitness tests, and a fasting blood draw. The follow-up visit, 24 weeks later, consists of a repeat of the same morning health visit.